alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1,001–1,025 of 10,985 studies · free to read (page 41 of 440) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease

✓ Peer-reviewed alzhub usefulness score 66 out of 100. JAMA neurology 2016-10-01

GBA mutations (β = 4.65; 95% CI, 1.72-7.58; P = .002), E326K (β = 3.42; 95% CI, 0.66-6.17; P = .02), and GBA variants combined as a single group (β = 4.01; 95% CI, 1.95-6.07; P = 1.5 × 10-4) were associated with a more rapid decline in MDS-UPDRS III score. 4 key findings →

Design: longitudinal study Participants: 740 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Predicting Alzheimer's disease progression using multi-modal deep learning approach

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Scientific reports 2019-02-13

Alzheimer's disease (AD) is a progressive neurodegenerative condition marked by a decline in cognitive functions with no validated disease modifying treatment. 1 key finding →

Design: cross-sectional Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Journal of Alzheimer's disease reports 2021-06-03

This fifteen-year study provides a large database of highly characterized individuals with longitudinal cognitive, imaging and lifestyle data and biofluid collections, to aid in the development of interventions to delay onset, prevent or treat AD. 1 key finding →

Design: cohort study Participants: 1,112 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Journal of neurology, neurosurgery, and psychiatry 2016-03-23

ADCOMS is proposed as new standard outcome for pAD and mild AD dementia trials, and is progressing in a CAMD-sponsored qualification process for use in registration trials of pAD. 3 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Prevalence, distribution, and impact of mild cognitive impairment in Latin America, China, and India: a 10/66 population-based study

✓ Peer-reviewed alzhub usefulness score 66 out of 100. PLoS medicine 2012-02-07

An algorithm-derived diagnosis of aMCI showed few sociodemographic associations but was consistently associated with higher disability and neuropsychiatric symptoms in addition to showing substantial variation in prevalence across LAMIC populations. 4 key findings →

Design: cross-sectional Participants: 15,376 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Meta-analysis of the association between variants in SORL1 and Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Archives of neurology 2011-01-01

Comprehensive and unbiased meta-analysis of all published and unpublished data from case-control studies for the SORL1 single-nucleotide polymorphisms (SNPs) that had been repeatedly assessed across studies. 4 key findings →

Design: meta-analysis Participants: 12,464 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies

✓ Peer-reviewed alzhub usefulness score 66 out of 100. JAMA neurology 2022-01-01

Alzheimer disease comorbid pathologic characteristics are common and are associated with more rapid cognitive decline in patients with dementia with Lewy bodies (DLB); therefore, it is anticipated that plasma p-tau concentrations may have utility in assessing cognitive impairment in individuals with this disorder. 4 key findings →

Design: cohort study Participants: 371 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Plasma Phosphorylated Tau at Threonine 181 and Neuropsychiatric Symptoms in Preclinical and Prodromal Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Neurology 2022-11-02

Plasma phosphorylated tau at threonine 181 (p-tau181), a well-validated marker of Alzheimer disease (AD) pathologic change, could be a more efficient way to diagnose AD than invasive or expensive biomarkers requiring CSF or PET. 4 key findings →

Design: cross-sectional Participants: 571 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study

✓ Peer-reviewed alzhub usefulness score 66 out of 100. PLoS medicine 2020-08-20

The ε4 allele of apolipoprotein E (APOE) gene and increasing age are two of the most important known risk factors for developing Alzheimer disease (AD). 4 key findings →

Design: cohort study Participants: 1,593 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts

✓ Peer-reviewed alzhub usefulness score 66 out of 100. The Lancet. Neurology 2017-06-16

Cognitive decline is a debilitating manifestation of disease progression in Parkinson's disease. 4 key findings →

Design: longitudinal study Participants: 3,200 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Predictors of cognitive impairment in an early stage Parkinson's disease cohort

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Movement disorders : official journal of the Movement Disorder Society 2014-01-06

The impact of Parkinson's disease (PD) dementia is substantial and has major functional and socioeconomic consequences. 4 key findings →

Design: longitudinal study Participants: 486 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE)

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Alzheimer's research & therapy 2018-09-19

We investigated the effect of crenezumab, a humanized anti-amyloid-beta (Aβ) immunoglobulin (Ig)G4 monoclonal antibody, on biomarkers of amyloid pathology, neurodegeneration, and disease progression in patients with mild-to-moderate Alzheimer's disease (AD). 4 key findings →

Participants: 26 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial

✓ Peer-reviewed alzhub usefulness score 66 out of 100. PloS one 2008-01-23

The objective of this study was to determine whether treatment with the nonselective nonsteroidal anti-inflammatory drug (NSAID) indomethacin slows cognitive decline in patients with Alzheimer's disease (AD). 4 key findings →

Participants: 51 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical Symptoms, and Genetics Among Patients With Late-Life Depression

✓ Peer-reviewed alzhub usefulness score 66 out of 100. JAMA psychiatry 2022-05-01

Late-life depression (LLD) is characterized by considerable heterogeneity in clinical manifestation. 4 key findings →

Design: longitudinal study Participants: 996 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Dementia is an age-independent risk factor for severity and death in COVID-19 inpatients

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2021-04-21

Dementia has been associated with COVID-19 prevalence, but whether this reflects higher infection, older age of patients, or disease severity remains unclear. 4 key findings →

Participants: 1,814 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Genome-wide meta-analysis of homocysteine and methionine metabolism identifies five one carbon metabolism loci and a novel association of ALDH1L1 with ischemic stroke

✓ Peer-reviewed alzhub usefulness score 66 out of 100. PLoS genetics 2014-03-20

Circulating homocysteine levels (tHcy), a product of the folate one carbon metabolism pathway (FOCM) through the demethylation of methionine, are heritable and are associated with an increased risk of common diseases such as stroke, cardiovascular disease (CVD), cancer and dementia. 4 key findings →

Design: meta-analysis Participants: 2,710 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Association of pro-inflammatory diet with increased risk of all-cause dementia and Alzheimer's dementia: a prospective study of 166,377 UK Biobank participants

✓ Peer-reviewed alzhub usefulness score 66 out of 100. BMC medicine 2023-07-21

Increasing evidence suggests an association between pro-inflammatory diets and cognitive function. 4 key findings →

Design: cohort study Participants: 1,372 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Shingles, Zostavax vaccination and risk of developing dementia: a nested case-control study-results from the UK Biobank cohort

✓ Peer-reviewed alzhub usefulness score 66 out of 100. BMJ open 2021-10-08

Data were drawn from the UK Biobank cohort study with a total of 228 223 participants with Hospital Episodes Statistics and primary care linkage health records. 4 key findings →

Design: cohort study Participants: 2,378 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed